Cardiovascular Outcomes of Upadacitinib/Baricitinib Versus Tofacitinib in Rheumatoid Arthritis: A Propensity-Matched Retrospective Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #441; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In this propensity-matched analysis of >27,000 RA patients from a nationally representative EHR network, tofacitinib was associated with significantly higher risks of mortality, MACE, heart failure, thromboembolic, and arrhythmic events compared to upadacitinib/baricitinib. These findings support the superior cardiovascular safety profile of for upadacitinib/baricitinib relative to tofacitinib and have important implications for therapeutic decision‑making, particularly in patients with elevated baseline cardiovascular risk, where agent selection may be tailored to minimize adverse outcomes. Table 1."
Retrospective data • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • JAK1 • JAK2
|
|
Rhytha Kasiraj; Vidhi Bhanushali; Arnav Lakkimsetti; Nikhila Ghanta; Manoja Gullapalli
|